4SC AG
4SC AG: 4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC 205 in China
DGAP-News: 4SC AG / Key word(s): Alliance 4SC enters into licensing and development partnership with Link Health for the cancer compound 4SC-205 in China Link Health will be responsible for clinical development and regulatory process for 4SC-205 in China whereas 4SC will receive upfront, milestone and royalty payments Planegg-Martinsried, Germany / Guangzhou, China, 31 May 2016 – 4SC AG (4SC, FSE Prime Standard: VSC) has entered into a licensing and development partnership for the cancer compound 4SC-205 with Guangzhou LingSheng Pharma Tech Co., Ltd (Link Health). Link Health will receive the exclusive licensing rights for the development and marketing of 4SC-205 in China, Hong Kong, Taiwan and Macao. In return, Link Health will be responsible for performing and financing the clinical development of 4SC-205. After successfully completing the clinical studies, Link Health will be responsible for regulatory approval at the CFDA (China Food and Drug Administration) and regional product marketing. The data generated may be used by 4SC to support further development of 4SC-205 in other key markets, such as Europe or the US. Under the agreement, 4SC will receive upfront and milestone payments totaling up to EUR 76 million from Link Health payable upon achieving specified development, regulatory and commercialization milestones. In addition, 4SC will be eligible to double-digit royalties linked to product sales of 4SC-205 in China. “We are very pleased to partner with Link Health having in-depth expertise in the clinical development, approval process and marketing of oncology products in this important Asian market,” comments Enno Spillner, CEO & CFO of 4SC. “Having shown promising results in the Phase I study in patients with advanced cancer, this partnership is an important step to ensure efficient further development of the cancer drug 4SC-205. On the other hand, in line with its strategic focus, 4SC can use its own financial resources for development of the epigenetic products resminostat and 4SC-202. In parallel, we are looking for further development and licensing opportunities for 4SC-205.” Dr Yan Song, CEO of Link Health, says: “We are proud to be given the opportunity to take over this innovative cancer product for our region and are planning an extensive clinical development program. Thanks to the promising preclinical and clinical data on 4SC-205, we have high hopes for this cancer drug and look forward to a productive and value-adding partnership.” – End of press release – Operating from the Chinese market, Link Health specializes in linking businesses from different markets to the mutual benefit of each other. The professional teams target and screen the best innovations in medical industry with the aim of creating market value in China with local partners. More information can be found at: www.healthinlink.com. 13 August 2015, 4SC strengthens patent protection for its epigenetic cancer drug candidate 4SC-202 in growth market China
2016-05-31 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | 4SC AG | |
Am Klopferspitz 19a | ||
82152 Planegg-Martinsried | ||
Germany | ||
Phone: | +49 (0)89 7007 63-0 | |
Fax: | +49 (0)89 7007 63-29 | |
E-mail: | public@4sc.com | |
Internet: | www.4sc.com | |
ISIN: | DE000A14KL72 | |
WKN: | A14KL7 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange | |
End of News | DGAP News Service |